S&P 500   5,254.35 (+0.11%)
DOW   39,807.37 (+0.12%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.05%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
S&P 500   5,254.35 (+0.11%)
DOW   39,807.37 (+0.12%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.05%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
S&P 500   5,254.35 (+0.11%)
DOW   39,807.37 (+0.12%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.05%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
S&P 500   5,254.35 (+0.11%)
DOW   39,807.37 (+0.12%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.05%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)

Eli Lilly and Company (LLY) Stock Price, News & Analysis

$777.96
-0.22 (-0.03%)
(As of 04:10 PM ET)
Today's Range
$776.44
$793.67
50-Day Range
$623.35
$792.28
52-Week Range
$334.58
$800.78
Volume
3.19 million shs
Average Volume
3.24 million shs
Market Capitalization
$739.19 billion
P/E Ratio
134.13
Dividend Yield
0.67%
Price Target
$689.52

Eli Lilly and Company MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.84 Rating Score
Upside/​Downside
11.8% Downside
$689.52 Price Target
Short Interest
Healthy
0.65% of Float Sold Short
Dividend Strength
Moderate
Based on Four Factors
Sustainability
-2.25
Upright™ Environmental Score
News Sentiment
0.45mentions of Eli Lilly and Company in the last 14 days
Based on 50 Articles This Week
Insider Trading
Selling Shares
$125.25 M Sold Last Quarter
Proj. Earnings Growth
47.83%
From $12.42 to $18.36 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.87 out of 5 stars

Medical Sector

36th out of 938 stocks

Pharmaceutical Preparations Industry

15th out of 433 stocks

LLY stock logo

About Eli Lilly and Company Stock (NYSE:LLY)

Eli Lilly and Company is a US-based multinational pharmaceutical company. It is the 12th largest pharmaceutical company by revenue and has offices in 16 countries. Its medicines are sold in at least 125 countries including its 8 blockbuster drugs. The company is a member of the S&P 500 and S&P 100 indices, it brought in roughly $5.5 billion in revenue for 2021 and employs more than 35,000 people across its network of research and production facilities.

Eli Lilly and Company was founded in 1876 by Colonel Eli Lilly. The colonel, a veteran of the Civil War, had recently dissolved an unsatisfactory partnership and set on his own to produce and develop medicinal chemicals. Colonel Lilly remained as president until his death in 1898. His charge to his family, company and coworkers was to “take what you find here and make it better and better”. The company is well-known for many drugs, including the first mass-marketing of quinine to treat malaria.

The company brought in $4,470 in its first year and saw that figure grow 10X over the next 3. Among the many innovations during this time period is the addition of gelation coatings for pills which helped set the company up for rapid expansion. The company was incorporated in 1881 as Eli Lilly and Company issuing stock to family and friends. The 1900s brought about more change for the company, change in the form of expansion which included international markets.

Advancements during the war years included increases in efficiency due to increased automation and the development of precision technologies. Among the technologies was pill manufacturing which included injecting medicines directly into a gelation capsule. This method allowed for more exact dosing, setting the standard for modern production. The company produced capsules for itself and sold excess capacity to competitors. Other major advancements include fruit flavorings in medicine, straight-line manufacturing and a method of blueprinting manufacturing tickets to prevent errors.

The modern period saw the company grow and discover new, world-class pharmaceuticals. Today, the company is engaged in the discovery, development and marketing of human pharmaceuticals. It offers a wide range of treatments, including Prozac but is perhaps most noteworthy for its work with insulin. The company is the first to mass produce insulin and has made numerous advances in treating diabetes in the time since. While other drugs are more widely known, its diabetic drugs Basaglar, Jardience, Trulicity, Humalog and Humulin are its top-sellers and contribute the bulk of revenue and cash flow.

Along with Diabetic research, the company also focuses on Alzheimer's, Oncology, Immunology, Obesity and Pain care. At the end of 2022, the company pipeline had 23 compounds in Phase 3 clinical trials and 1 in review. There were another 18 in Phase 2 trials and more than 2 dozen in Phase 1 trials. The average cost to discover a new drug was running at $2.6 billion with a 10-year discovery-to-patient timeline.

LLY Stock Price History

LLY Stock News Headlines

7 Stocks That Will Drive the Weight Loss Drugs Market (LLY)
The booming weight loss drug market presents both lucrative potential and significant risks for investors seeking to capitalize on the global obesity crisis.
Nvidia's AI Tech Part of Novo Nordisk's New Supercomputer (LLY)
Novo Nordisk and Nvidia have teamed up to develop supercomputers, aiming to accelerate drug discovery development using advanced AI technologies.
This consistently signaled gains of 453%... 610%... and even 1036%...
It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.
LifeMD Shares Come Back to Life on GLP-1 Business Growth (LLY)
LifeMD stock is surging as the company is riding the GLP-1 trend to double-digit revenue growth and projections for 67% earnings growth in 2024
Can WeightWatchers Regain its Mojo after Oprah Steps Down? (LLY)
WW International Inc. (NASDAQ: WW) (WeightWatchers) has had a disastrous 2024, with its shares collapsing 66.7% year-to-date (YTD).
Can WeightWatchers Regain Its Mojo after Oprah Steps Down?
WW International Inc. NASDAQ: WW (WeightWatchers) has had a disastrous 2024, with its shares collapsing 66.7% year-to-date (YTD). The company made a praiseworthy strategic pivot in 2023, acquiring Sequence Inc. to enter into the GLP-1 clinical weight loss space, gaining the ability to prescribe medications like Novo Nordisk A/V NYSE: NVO owned Ozempic and Wegovy and Eli Lilly& Co. NYSE: LLY GLP-1 agonists like Mounjaro and Zepbound.
MarketBeat Week in Review – 3/4 – 3/8 (LLY)
The market rally continues as the February Jobs Report reignited the soft landing talk, but momentum could stall if next week's inflation readings come in hot
Are These 5 Undervalued Stocks Ready to Break Out? (LLY)
Undervalued stocks Albemarle, Ionis, Insulet, Hess and Wynn beat earnings views, offering potential for investors to buy quality companies at discounted prices.
Altcoin FRENZY Alert…
Bitcoin recently crossed the highest price in its 15-year history… Less than 2 years after one of the most vicious crypto market meltdowns we've ever seen! Bitcoin's BOOM also sent shockwaves through the altcoin market, with select coins seeing HUGE moves in a matter of days… Like Fetch.ai, that gained over 350% in just the last 30 days…
Beam Therapeutics Bolts Higher on Gene Therapy Licensing Payments (LLY)
Beam Therapeutics stock is rising as the company begins to receive significant money from the multiple licensing deals it has in place
Vivani Medical Surges on its Ozempic-Like Weight-Loss Implant (LLY)
The Ozempic craze continues to make headlines in the medical sector, and GLP-1 drug stocks such as Vivani Medical continue to surge higher
3 Stocks Showing Constructive Pullbacks with Indexes at New Highs
One of the most exciting things for an investor or trader is to look at tier account statement, or at the charts of what they own, and see a stock like Nvidia Corp. NASDAQ: NVDA or even the broader SPDR S&P 500 ETF Trust NYSEARCA: SPY or Invesco QQQ NASDAQ: QQQ rallying to new highs.
Insiders Are Dumping These 10 Healthcare Stocks
10 Best Stocks To Buy For Grandchildren
See More Headlines
Receive LLY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eli Lilly and Company and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/06/2024
Ex-Dividend for 3/8 Dividend
2/14/2024
Dividend Payable
3/08/2024
Today
3/28/2024
Next Earnings (Estimated)
4/25/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
CUSIP
53245710
Employees
43,000
Year Founded
1876

Price Target and Rating

Average Stock Price Target
$689.52
High Stock Price Target
$1,000.00
Low Stock Price Target
$392.00
Potential Upside/Downside
-12.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.84
Research Coverage
19 Analysts

Profitability

Net Income
$5.24 billion
Pretax Margin
19.21%

Debt

Sales & Book Value

Annual Sales
$34.12 billion
Cash Flow
$7.71 per share
Book Value
$11.44 per share

Miscellaneous

Free Float
948,929,000
Market Cap
$744.12 billion
Optionable
Optionable
Beta
0.34

Social Links

Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

Should I Buy Eli Lilly and Company Stock? LLY Pros and Cons Explained

These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of Eli Lilly and Company was last updated on Monday, March 25, 2024 at 11:21 PM.

Pros

Here are some ways that investors could benefit from investing in Eli Lilly and Co:

  • Eli Lilly and Company offers a diverse range of pharmaceutical products, including innovative treatments for various medical conditions such as diabetes, oncology, rheumatoid arthritis, and more.
  • The company has a strong pipeline of drugs in development, indicating potential for future growth and revenue generation.
  • Recent collaborations with reputable pharmaceutical companies like Incyte Corporation and Boehringer Ingelheim Pharmaceuticals can lead to new breakthrough products and expanded market presence.
  • Eli Lilly's stock price has shown resilience and growth in recent periods, reflecting positive investor sentiment and potential for capital appreciation.
  • The company's focus on research and development ensures a continuous stream of new products, enhancing competitiveness and market relevance.

Cons

Investors should be bearish about investing in Eli Lilly and Co for these reasons:

  • Market competition in the pharmaceutical industry is intense, leading to pricing pressures and potential challenges in maintaining market share.
  • Regulatory uncertainties and changes in healthcare policies can impact the company's product approvals and market access, affecting revenue streams.
  • Dependency on a few key products for a significant portion of revenue poses risks in case of patent expirations or market disruptions.
  • Potential adverse effects of global economic conditions or health crises on pharmaceutical demand and supply chains may impact Eli Lilly's financial performance.
  • Investing in pharmaceutical companies involves inherent risks related to clinical trial outcomes, regulatory compliance, and market acceptance of new products.

LLY Stock Analysis - Frequently Asked Questions

Should I buy or sell Eli Lilly and Company stock right now?

19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eli Lilly and Company in the last year. There are currently 3 hold ratings and 16 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" LLY shares.
View LLY analyst ratings
or view top-rated stocks.

What is Eli Lilly and Company's stock price target for 2024?

19 Wall Street research analysts have issued 12-month target prices for Eli Lilly and Company's stock. Their LLY share price targets range from $392.00 to $1,000.00. On average, they predict the company's share price to reach $689.52 in the next twelve months. This suggests that the stock has a possible downside of 11.8%.
View analysts price targets for LLY
or view top-rated stocks among Wall Street analysts.

How have LLY shares performed in 2024?

Eli Lilly and Company's stock was trading at $582.92 at the beginning of 2024. Since then, LLY stock has increased by 34.2% and is now trading at $782.04.
View the best growth stocks for 2024 here
.

Are investors shorting Eli Lilly and Company?

Eli Lilly and Company saw a increase in short interest in the month of February. As of February 29th, there was short interest totaling 5,420,000 shares, an increase of 5.2% from the February 14th total of 5,150,000 shares. Based on an average daily trading volume, of 3,280,000 shares, the days-to-cover ratio is currently 1.7 days. Approximately 0.6% of the shares of the stock are short sold.
View Eli Lilly and Company's Short Interest
.

When is Eli Lilly and Company's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 25th 2024.
View our LLY earnings forecast
.

How were Eli Lilly and Company's earnings last quarter?

Eli Lilly and Company (NYSE:LLY) issued its earnings results on Tuesday, February, 6th. The company reported $2.49 earnings per share for the quarter, beating the consensus estimate of $2.30 by $0.19. The business had revenue of $9.35 billion for the quarter, compared to analysts' expectations of $8.95 billion. Eli Lilly and Company had a net margin of 15.36% and a trailing twelve-month return on equity of 51.22%. The company's revenue was up 28.1% compared to the same quarter last year. During the same period last year, the company posted $2.09 earnings per share.
Read the conference call transcript
.

How often does Eli Lilly and Company pay dividends? What is the dividend yield for Eli Lilly and Company?

Eli Lilly and Company announced a quarterly dividend on Friday, December 8th. Investors of record on Thursday, February 15th will be given a dividend of $1.30 per share on Friday, March 8th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.66%. The ex-dividend date of this dividend is Wednesday, February 14th. This is a positive change from the stock's previous quarterly dividend of $1.13.
Read our dividend analysis for LLY
.

Is Eli Lilly and Company a good dividend stock?

Eli Lilly and Company (NYSE:LLY) pays an annual dividend of $5.20 per share and currently has a dividend yield of 0.67%. The company has been increasing its dividend for 10 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 89.66%. Payout ratios above 75% are not desirable because they may not be sustainable. Based on earnings estimates, LLY will have a dividend payout ratio of 28.32% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for LLY.

What guidance has Eli Lilly and Company issued on next quarter's earnings?

Eli Lilly and Company issued an update on its FY24 earnings guidance on Tuesday, February, 6th. The company provided earnings per share guidance of $12.20-12.70 for the period, compared to the consensus earnings per share estimate of $12.39. The company issued revenue guidance of $40.4-41.6 billion, compared to the consensus revenue estimate of $39.27 billion.

What is David A. Ricks' approval rating as Eli Lilly and Company's CEO?

399 employees have rated Eli Lilly and Company Chief Executive Officer David A. Ricks on Glassdoor.com. David A. Ricks has an approval rating of 86% among the company's employees.

What other stocks do shareholders of Eli Lilly and Company own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Eli Lilly and Company investors own include Johnson & Johnson (JNJ), Pfizer (PFE), NVIDIA (NVDA), Intel (INTC), Cisco Systems (CSCO), Bristol-Myers Squibb (BMY), Walt Disney (DIS), AT&T (T), Verizon Communications (VZ) and JPMorgan Chase & Co. (JPM).

Who are Eli Lilly and Company's major shareholders?

Eli Lilly and Company's stock is owned by a number of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (7.54%), PNC Financial Services Group Inc. (5.44%), Capital World Investors (2.84%), Primecap Management Co. CA (2.34%), Price T Rowe Associates Inc. MD (2.30%) and State Farm Mutual Automobile Insurance Co. (1.72%). Insiders that own company stock include Acquisition Corp Kearny, Alonzo Weems, Anne E White, Donald A Zakrowski, Ilya Yuffa, Jackson P Tai, Johna Norton, Lilly Endowment Inc, Marschall S Runge and Patrik Jonsson.
View institutional ownership trends
.

How do I buy shares of Eli Lilly and Company?

Shares of LLY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Eli Lilly and Company have any subsidiaries?
The following companies are subsidiares of Eli Lilly and Company: 1096401 B.C. Unlimited Liability Company, ARMO Biosciences Inc., Acanthas Pharma Inc., Advanced Cardiovascular Systems, Alnara Pharmaceuticals, Alnara Pharmaceuticals Inc., Andean Technical Operations Center, Applied Molecular Evolution Inc., AurKa Pharma Inc., Avid Radiopharmaceuticals, Avid Radiopharmaceuticals Inc., ChemGen, CoLucid Pharmaceuticals, CoLucid Pharmaceuticals Inc., Compania Farmaceutica Eli Lilly de Centro America S.A., Dermira, Dermira Canada, Dermira Inc., Devices for Vascular Intervention(DVI), Disarm Therapeutics, Disarm Therapeutics, Disarm Therapeutics Inc., Dista Ilac Ticaret Ltd. Sti., Dista S.A., Dista-Produtos Quimicos & Farmaceuticos LDA, ELCO Dominicana SRL, ELCO Insurance Company Limited, ELCO Management Inc., ELCO for Trade and Marketing S.A.E., ELGO Insurance Company Limited, Elanco Animal Health Ireland Limited, Elanco Switzerland Holding Sarl, Eli Lilly (Malaysia) Sdn. Bhd., Eli Lilly (Philippines) Incorporated, Eli Lilly (S.A.) (Proprietary) Limited, Eli Lilly (Singapore) Pte. Ltd., Eli Lilly (Suisse) S.A., Eli Lilly Asia Inc., Eli Lilly Asia Pacific SSC Sdn Bhd, Eli Lilly Australia Pty. Limited, Eli Lilly B-H d.o.o., Eli Lilly Benelux S.A., Eli Lilly Bienes y Servicios S de RL de CV, Eli Lilly CR s.r.o., Eli Lilly Canada Inc., Eli Lilly Cork Limited, Eli Lilly Danmark A/S, Eli Lilly Egypt for Trading, Eli Lilly European Clinical Trial Services SA, Eli Lilly Export S.A., Eli Lilly Finance S.A., Eli Lilly Ges.m.b.H., Eli Lilly Group Limited, Eli Lilly Holdings Ltd., Eli Lilly Hrvatska d.o.o., Eli Lilly Interamerica Inc., Eli Lilly Interamerica Inc. y Compania Limitada, Eli Lilly International Corporation, Eli Lilly Ireland Holdings Limited, Eli Lilly Israel Ltd., Eli Lilly Italia S.p.A., Eli Lilly Japan K.K., Eli Lilly Kinsale Limited, Eli Lilly Nederland B.V., Eli Lilly Nigeria Ltd., Eli Lilly Norge A.S., Eli Lilly Pakistan (Pvt.) Ltd., Eli Lilly Polska Sp.z.o.o. (Ltd.), Eli Lilly Regional Operations GmbH, Eli Lilly Romania SRL, Eli Lilly S.A., Eli Lilly Saudi Arabia Limited, Eli Lilly Services India Private Limited, Eli Lilly Slovakia s.r.o., Eli Lilly Sweden AB, Eli Lilly Vostok S.A. Geneva, Eli Lilly and Company, Eli Lilly and Company (India) Pvt. Ltd., Eli Lilly and Company (Ireland) Limited, Eli Lilly and Company (N.Z.) Limited, Eli Lilly and Company (Taiwan) Inc., Eli Lilly and Company Limited, Eli Lilly do Brasil Limitada, Eli Lilly farmacevtska druzba d.o.o., Eli Lilly y Compania de Mexico S.A. de C.V., Eli Lilly y Compania de Venezuela S.A., Glycostasis Inc., Greenfield-Produtos Farmaceuticos Lda., Heart Rhythm Technologies Inc, Hybritech, Hypnion, ICOS Corporation, ICOS Corporation, ImClone GmbH, ImClone LLC, ImClone Systems Holdings Inc., ImClone Systems LLC, Imclone Systems, Irisfarma S.A., Ivy Animal Health, LDH I Corporation, Lilly (Shanghai) Management Co. Ltd., Lilly Asia Ventures Fund I L.P., Lilly Asia Ventures Fund II L.P., Lilly Asian Ventures Fund III L.P., Lilly Cayman Holdings, Lilly Centre for Clinical Pharmacology PTE. LTD., Lilly China Research and Development Co. Ltd, Lilly Deutschland GmbH, Lilly France S.A.S., Lilly Global Nederland Holdings B.V., Lilly Global Services Inc., Lilly Holding GmbH, Lilly Holdings B.V., Lilly Hungaria KFT, Lilly Japan Financing G.K., Lilly Korea Ltd., Lilly Nederland Finance B.V., Lilly Nederland Finance B.V. - GCC, Lilly Nederland Holding B.V., Lilly Pharma Ltd., Lilly Portugal - Produtos Farmaceuticos Lda., Lilly S.A., Lilly Suzhou Pharmaceutical Co. Ltd., Lilly Trading Co. LTD, Lilly USA LLC, Lilly Ventures Fund I LLC, Lilly del Caribe Inc., Lilly ilaç ticaret limited şirketi, Lohmann Animal Health, Loxo Oncology, Loxo Oncology Inc., Novartis Animal Health, OY Eli Lilly Finland AB, Origin Medsystems, PT. Eli Lilly Indonesia, Pacific Biotech, Petra Pharma Corporation, Pharmaserve-Lilly S.A.C.I., Pharmaserve-Lilly S.A.C.I., Physio-Control, Prevail Therapeutics Inc., Protomer Technologies, SGX Pharmaceuticals, SGX Pharmaceuticals Inc., Spaly Bioquimica S.A., UAB Eli Lilly Lietuva, Valquifarma S.A., and Vital Pharma Productos Farmaceuticos.
Read More
This page (NYSE:LLY) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners